ValuEngine upgraded shares of Novartis (NYSE:NVS) from a sell rating to a hold rating in a research note released on Wednesday.

Other analysts have also recently issued reports about the company. Exane BNP Paribas raised Novartis from an underperform rating to a neutral rating in a research report on Tuesday, September 11th. Barclays raised Novartis from an underweight rating to an equal weight rating in a research report on Thursday, July 19th. Zacks Investment Research raised Novartis from a sell rating to a hold rating in a research report on Tuesday, June 19th. Credit Suisse Group raised Novartis from an underperform rating to a neutral rating in a research report on Friday, May 25th. Finally, Citigroup raised Novartis from a neutral rating to a buy rating in a research report on Tuesday, September 11th. One analyst has rated the stock with a sell rating, eleven have issued a hold rating and three have assigned a buy rating to the company. The stock currently has a consensus rating of Hold and an average target price of $87.24.

NYSE:NVS opened at $85.22 on Wednesday. The company has a market cap of $195.66 billion, a P/E ratio of 17.72, a PEG ratio of 1.77 and a beta of 0.85. The company has a current ratio of 1.15, a quick ratio of 0.89 and a debt-to-equity ratio of 0.30. Novartis has a 52-week low of $72.30 and a 52-week high of $94.19.

Novartis (NYSE:NVS) last released its quarterly earnings results on Wednesday, July 18th. The company reported $1.29 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.27 by $0.02. The firm had revenue of $13.16 billion for the quarter, compared to the consensus estimate of $12.93 billion. Novartis had a return on equity of 16.05% and a net margin of 27.06%. The firm’s quarterly revenue was up 7.5% compared to the same quarter last year. During the same quarter last year, the business posted $1.22 EPS. research analysts expect that Novartis will post 5.17 EPS for the current fiscal year.

In other Novartis news, major shareholder Bioventures Ltd Novartis sold 30,600 shares of the stock in a transaction that occurred on Monday, July 23rd. The stock was sold at an average price of $4.25, for a total transaction of $130,050.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders have sold a total of 81,322 shares of company stock valued at $290,796 over the last ninety days. 0.01% of the stock is owned by insiders.

A number of institutional investors have recently bought and sold shares of the business. Winthrop Partners WNY LLC acquired a new stake in shares of Novartis in the 1st quarter valued at approximately $100,000. Gables Capital Management Inc. acquired a new stake in shares of Novartis in the 1st quarter valued at approximately $103,000. Quad Cities Investment Group LLC acquired a new stake in shares of Novartis in the 2nd quarter valued at approximately $139,000. Archford Capital Strategies LLC acquired a new stake in shares of Novartis in the 1st quarter valued at approximately $149,000. Finally, Moneta Group Investment Advisors LLC acquired a new stake in shares of Novartis in the 2nd quarter valued at approximately $174,000. 11.16% of the stock is owned by institutional investors.

About Novartis

Novartis AG researches, develops, manufactures, and markets a range of healthcare products worldwide. The company's Innovative Medicines segment offers patented prescription medicines to enhance health outcomes for patients and health-care providers. This segment also commercializes products in the areas of oncology and rare diseases, ophthalmology, immunology and dermatology, neuroscience, respiratory, cardio-metabolic, and established medicines.

Featured Article: Investing in Dividend Stocks

To view ValuEngine’s full report, visit ValuEngine’s official website.

Analyst Recommendations for Novartis (NYSE:NVS)

Receive News & Ratings for Novartis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novartis and related companies with MarketBeat.com's FREE daily email newsletter.